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ABSTRACT Traditional approaches to drug discovery are frustratingly inefﬁcient and
have several key limitations that severely constrain our capacity to rapidly identify
and develop novel experimental therapeutics. To address this, we have devised a
second-generation target-based whole-cell screening assay based on the principles
of competitive ﬁtness, which can rapidly identify target-speciﬁc and physiologically
active compounds. Brieﬂy, strains expressing high, intermediate, and low levels of a
preselected target protein are constructed, tagged with spectrally distinct ﬂuores-
cent proteins (FPs), and pooled. The pooled strains are then grown in the presence
of various small molecules, and the relative growth of each strain within the mixed
culture is compared by measuring the intensity of the corresponding FP tags.
Chemical-induced population shifts indicate that the bioactivity of a small molecule
is dependent upon the target protein’s abundance and thus establish a speciﬁc
functional interaction. Here, we describe the molecular tools required to apply this
technique in the prevalent human fungal pathogen Candida albicans and validate
the approach using two well-characterized drug targets—lanosterol demethylase
and dihydrofolate reductase. However, our approach, which we have termed target
abundance-based ﬁtness screening (TAFiS), should be applicable to a wide array of
molecular targets and in essentially any genetically tractable microbe.
IMPORTANCE Conventional drug screening typically employs either target-based or
cell-based approaches. The ﬁrst group relies on biochemical assays to detect modu-
lators of a puriﬁed target. However, hits frequently lack drug-like characteristics such
as membrane permeability and target speciﬁcity. Cell-based screens identify com-
pounds that induce a desired phenotype, but the target is unknown, which severely
restricts further development and optimization. To address these issues, we have de-
veloped a second-generation target-based whole-cell screening approach that incor-
porates the principles of both chemical genetics and competitive ﬁtness, which en-
ables the identiﬁcation of target-speciﬁc and physiologically active compounds from
a single screen. We have chosen to validate this approach using the important hu-
man fungal pathogen Candida albicans with the intention of pursuing novel antifun-
gal targets. However, this approach is broadly applicable and is expected to dramati-
cally reduce the time and resources required to progress from screening hit to lead
compound.
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The process of drug discovery, development, and approval often takes more than adecade, with a recent report estimating the associated costs at over $2.5 billion (1).
As such, there is an urgent need to increase the efﬁciency with which new experimental
therapeutics are discovered and developed. This is especially true for antifungal
development, with the newest class of antifungal drugs, the echinocandins, taking
30 years to reach patients (2). High attrition rates at both the preclinical and clinical
stages prolong this timeline and greatly increase the associated costs. Many failures
occur because hit compounds selected from the initial chemical screening steps lack
the qualities of an effective therapy, such as target speciﬁcity or membrane permea-
bility. This is a direct result of the signiﬁcant limitations of the two approaches most
widely adopted to seek chemicals with the desired activity. Target-based screens
require the development of a biochemical assay that is utilized to identify inhibitors or
activators of a puriﬁed target protein. While this is an effective strategy to identify
potent chemical modulators of the target protein, many have poor membrane perme-
ability or do not otherwise engage the target protein in its native environment. As such,
many hits from target-based screens lack activity upon whole cells or are later found to
lack target speciﬁcity and consequently have unintended off-target effects and/or
toxicity. This necessitates costly efforts to improve cell permeability and/or selective
target engagement that are often unsuccessful. Thus, hits obtained through target-
based screens have not translated well into clinically useful antimicrobial agents (3).
Furthermore, many proteins are not amenable to puriﬁcation or high-throughput
(HTP)-compatible biochemical assays and thus are not suited for target-based chemical
screens. Whole-cell-based screens identify compounds that induce or correct a disease-
relevant phenotype (e.g., inhibition of microbial growth), but the molecular target and
mechanism of action (MOA) of each hit are unknown. Identiﬁcation of the molecular
target then requires a substantial investment of time and resources, without which
further development and optimization of promising lead compounds toward a viable
therapeutic is severely restricted (4, 5). Thus, with either strategy, the identiﬁcation of
pharmacologically active agents that act via a deﬁned MOA is a multistep process.
Signiﬁcant increases in the efﬁciency of drug discovery and development can be
achieved through the rapid identiﬁcation of physiologically active hits that act upon a
speciﬁc target protein or pathway within living cells. Furthermore, the elimination of
agents that lack the requisite target speciﬁcity during primary screening would also
yield dramatic cost and time savings.
The purpose of this study was to establish and validate an innovative HTP screening
strategy that can dramatically improve the efﬁciency with which target-speciﬁc and
physiologically active chemical probes are identiﬁed. Our approach is a type of target-
based whole-cell screen (TB-WCS), which refers to the identiﬁcation of chemical probes
that functionally interact with a selected target protein within intact cells (6). Like
previous TB-WCS screens, our method, which we have termed target abundance-based
ﬁtness screening (TAFiS), relies on the fundamental principles of chemical genetics—
that altering the abundance of a target protein usually affects a cell’s susceptibility to
chemical modulators of that target (7). However, TAFiS also integrates the principle of
competitive ﬁtness to enhance the efﬁciency and sensitivity of the screening assay and
incorporates ﬂuorescent protein (FP) tags to facilitate quantitative measurement of the
chemical-target interaction. To provide proof of principle, we have developed the tools
and methodology necessary to conduct TAFiS in the prevalent human fungal pathogen
Candida albicans. We also validated TAFiS using two well-characterized drug targets:
lanosterol demethylase (Erg11p)—the target of the azole antifungals—and dihydrofo-
late reductase (Dfr1p). However, the approach we have developed is broadly applicable
and can theoretically be applied to almost any target and in any genetically tractable
microbe.
RESULTS
Design of TAFiS assay. Strains expressing high (THi), low (TLo), or intermediate
(TMed) levels of the desired target protein are constructed, and each is labeled with a
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spectrally distinct ﬂuorescent protein (FP) tag. The tagged strains are then mixed
together to form an expression pool that is used to screen compounds and identify
those that differentially affect the growth of each strain. The resulting chemical-induced
population shift can be detected spectroscopically and indicates that a compound’s
bioactivity depends upon the abundance of the target protein—therefore establishing
a functional chemical-target interaction (Fig. 1). As such, TAFiS depends upon two key
technical challenges: (i) the capacity to label individual C. albicans strains with sufﬁ-
ciently bright and spectrally distinct FP tags and (ii) the stratiﬁcation of target protein
expression between THi, TMed, and TLo strains.
Selection and optimization of ﬂuorescent protein tags. The coding sequences of
several previously reported FPs (8–15) were cloned into expression vectors, which were
then stably integrated into the genome of C. albicans, and the ﬂuorescence intensity of
each FP-tagged strain was compared to that of an untagged strain transformed with
vector alone. The strains were grown in 96-well plates in yeast nitrogen base (YNB)
medium at 30°C for 48 h to mimic the proposed conditions of the chemical screen,
before ﬂuorescence intensity was measured at the reported excitation and emission
maxima of each FP. Of those tested, the three brightest FP tags under the proposed
assay conditions were cerulean (CER), green ﬂuorescent protein gamma (GFP), and
dTomato (dTOM) (see Fig. S1A in the supplemental material). We next examined the
degree of cross-excitation between these three FP tags by measuring the ﬂuorescence
signal of each tagged strain at each of the FP wavelengths. Minimal spectral overlap
was detected between CER-, GFP-, and dTOM-tagged strains (Fig. S1B), and these
three FPs were therefore used in subsequent work. We next conﬁrmed that the relative
abundance of each tagged strain within a mixed culture can be accurately quantiﬁed
through ﬂuorescence detection. Three wild-type C. albicans strains tagged with each FP
were mixed in deﬁned ratios and grown in 96-well plates. After 24 and 48 h, the
ﬂuorescence intensity of each FP tag was measured and plotted against the original
inoculum. This produced a linear correlation with excellent R2 values for each FP-
tagged strain (Fig. S1C). Finally, we examined if high-level expression of CER, GFP, or
dTOM was detrimental to C. albicans ﬁtness by comparing the capacity of each tagged
strain to endure a variety of stresses to that of an untagged control strain, including
elevated temperature, osmotic and ionic stresses, as well as the presence of cell wall-
and membrane-perturbing agents. While the FP-tagged strains grew marginally slower
than the untagged control strain under standard culture conditions (presumably as a
result of the metabolic load of FP production), the effect was of similar magnitude
irrespective of the FP tag expressed. The FP-tagged strains did not exhibit any addi-
tional abnormal phenotypes under any of the stress conditions tested (see Fig. S2 in the
supplemental material).
Construction of Candida albicans strains with an Erg11p expression differen-
tial. Lanosterol demethylase (Erg11p), an enzyme involved in the biosynthesis of the
membrane lipid ergosterol, is inhibited by the azole antifungals and is the best-
FIG 1 Schematic of the target abundance-based ﬁtness screening (TAFiS) assay. A panel of strains expressing high (THi), medium (TMed),
or low (TLo) levels of the selected target are constructed, tagged with spectrally distinct ﬂuorescent proteins (FP), and pooled. The
expression pool is then incubated in the presence of various small molecules, and the relative growth of each strain is quantiﬁed by
measuring ﬂuorescence. On-target inhibitors should differentially impact the growth of each strain causing a chemical-induced population
shift that can be detected as a shift in ﬂuorescence compared to the untreated control.
TAFiS in C. albicans
September/October 2017 Volume 2 Issue 5 e00379-17 msphere.asm.org 3
 o
n
 D
ecem
ber 7, 2017 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
characterized drug target described in fungi. We therefore used Erg11p to validate the
TAFiS assay and test its reliability to detect on-target inhibitors. An Erg11p overexpres-
sion strain was produced by introducing an additional copy of ERG11 into a wild-type
(ERG11/ERG11) C. albicans strain, using an expression vector with the powerful PTEF1
transcriptional promoter. To suppress Erg11p expression, an ERG11/erg11 heterozy-
gous strain was constructed, through replacement of one ERG11 allele with the ARG4
selection marker. Since Erg11p is an essential protein (16), it is not possible to construct
an erg11/ deletion mutant. Therefore, to further suppress Erg11p expression, the
native promoter of the remaining ERG11 allele in the heterozygous strain was replaced
with one of several C. albicans promoter sequences (Fig. 2A). This promoter replace-
ment strategy should disrupt the Upc2p-mediated transcriptional activation of ERG11
that occurs following azole-mediated sterol depletion (17). Such feedback loops directly
oppose our goal of maximizing the Erg11p expression differential. In this fashion, a
panel of six additional C. albicans strains with altered ERG11 genotypes were generated.
Western blot analysis of cell extracts revealed that relative Erg11p expression levels
varied by 50-fold among the engineered strains (Fig. 2B).
We next conﬁrmed that changes in Erg11p abundance altered C. albicans suscep-
tibility to the on-target inhibitor ﬂuconazole. Dose-response experiments conﬁrmed
that ﬂuconazole susceptibility differed by 1,000-fold between the highest- and
lowest-Erg11p-expressing strains (Fig. 2C and D). The lowest-Erg11p-expressing strain
(erg11Δ/PVPS21-ERG11) has a pronounced slow-growth phenotype, indicating that the
Erg11p level is below some critical threshold required for normal C. albicans growth
(see Fig. S3 in the supplemental material). Due to its poor growth, the erg11/PVPS21-
ERG11 strain was not used in subsequent experiments.
Chemical-target interactions can be detected as spectroscopic shifts in the
FP-tagged expression pools. Strains expressing high (Erg11Hi), intermediate
(Erg11Med), and low (Erg11Lo) levels of Erg11p were each tagged with an FP expression
construct. Two Erg11p expression pools were then created by combining equal
proportions of (i) the ERG11/ERG11/PTEF1-ERG11::CER (Erg11Hi), ERG11/ERG11::dTOM
(Erg11Med), and ERG11/erg11::GFP (Erg11Lo) gene dosage strains or (ii) The erg11/
PTEF1-ERG11::CER (Erg11Hi), erg11/PYPT52-ERG11::dTOM (Erg11Med), and erg11/PACT1-
ERG11::GFP (Erg11Lo) promoter replacement strains. These pools were then utilized in
coculture experiments to examine how an on-target inhibitor affects the composition
of each population. A total of approximately 103 cells from each expression pool,
consisting of the three strains in equal proportions, were seeded to the wells of a
96-well plate in YNB medium and grown for 48 h in the presence of various concen-
trations of ﬂuconazole. Fluorescence intensity was quantiﬁed for each tag and com-
pared to the minus-drug (dimethyl sulfoxide [DMSO]) control. As expected, substantive
population shifts favoring the Erg11Hi strains were detected in both expression pools
over a large range of ﬂuconazole concentrations compared to wells containing DMSO
alone (Fig. 3A and B). Similar population shifts, favoring the Erg11Hi strain, were
observed using a selection of other azole antifungals, including miconazole and
voriconazole (see Fig. S4A and B in the supplemental material). Furthermore, the
speciﬁc concentration ranges over which the population shifts occurred reﬂects the
relative potency of each azole. When the same dose-response experiments were
performed with a pool of three wild-type (ERG11/ERG11) strains (i.e., with no Erg11p
expression differential), tagged with CER, GFP, or dTOM, no signiﬁcant spectral shifts
were detected (Fig. 3D). This conﬁrmed that the azole-induced population shifts
observed in the Erg11p expression pools are the result of differential Erg11p expression,
rather than interference with ﬂuorescent protein signals. However, when similar exper-
iments were performed with terbinaﬁne, a drug that inhibits squalene epoxidase
(Erg1p), an enzyme acting upstream of Erg11p (Fig. S4C), or fenpropimorph, which
inhibits two enzymes (Erg2p and Erg24p) acting downstream of Erg11p (data not
shown), no signiﬁcant population shifts were detected in the Erg11p expression pool at
any concentration. Furthermore, amiodarone and cyclosporine, chemical agents known
to synergize with the azole antifungals, did not induce spectral shifts in the tagged
Butts et al.
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FIG 2 Altering Erg11p expression levels dramatically affects C. albicans susceptibility to ﬂuconazole. (A)
Schematic of strain construction. (B) C. albicans strains were grown into the exponential phase, and
whole-cell lysate was prepared and analyzed by Western immunoblotting with anti-Erg11p, as well as
anti-PSTAIRE (an internal loading control). (C and D) C. albicans strains were grown in YNB at 30°C in the
presence of various concentrations of ﬂuconazole. After 48 h, growth was measured as OD600 and
expressed as a percentage of that of the untreated control. The values presented are the averages of
technical triplicates and are representative of two independent experiments.
TAFiS in C. albicans
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FIG 3 Fluconazole induces a population shift within the FP-tagged Erg11p expression pools over a broad
concentration range. Approximately 103 cells of the indicated pool were inoculated into the wells of a
96-well plate in the presence of a range of ﬂuconazole concentrations in YNB. After 48 h at 30°C,
ﬂuorescence was read at all three FPs’ wavelengths and expressed as a percentage of ﬂuorescence of the
untreated wells. The values presented are the averages and standard deviations of technical triplicates.
(A) C. albicans ERG11/ERG11/PTEF1-ERG11::CER (Erg11Hi), ERG11/ERG11::dTOM (Erg11Med), and ERG11/
erg11Δ::GFP (Erg11Lo) strains were mixed in equal proportions to create a gene dosage expression pool.
(Continued on next page)
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Erg11p expression pool (data not shown). Finally, an antifungal drug with an MOA
unrelated to ergosterol biosynthesis, caspofungin, equally affected the growth of all
strains within the expression pool (Fig. S4D) Collectively these results demonstrate that
chemical-induced population shifts within an FP-tagged expression pool indicate a
highly speciﬁc chemical-target interaction.
Validation of TAFiS as a chemical screening strategy. We next determined if
TAFiS can provide the basis of a robust HTP chemical screening assay. In order to
maximize the Erg11p expression differential and increase the dynamic range of our
screen, we created a new hybrid expression pool composed of ERG11/ERG11/PTEF1-
ERG11::CER (Erg11Hi), ERG11/ERG11::dTOM (Erg11Med), and erg11/PACT1-ERG11::GFP
(Erg11Lo) strains. This pool was then grown in YNB medium in 96-well plates with and
without ﬂuconazole. To provide a single metric of comparative strain growth in each
well, a relative ﬁtness differential (Rd) was calculated as the log10 ﬂuorescence intensity
ratio of the Erg11Hi and Erg11Lo strains. Z= factors (18) were then calculated from the
Rd scores of the Erg11 expression pool grown with and without ﬂuconazole. The Z=
factors were 0.86  0.04 with 5 M ﬂuconazole and 0.57  0.05 with 0.1 M
ﬂuconazole, indicating excellent reproducibility of the assay and conﬁrming its suit-
ability for HTP screening applications.
Finally, we tested the reliability of a TAFiS-based HTP screen to identify on-target
chemical probes. The hybrid Erg11p pool was used to screen the NCC (719 compounds)
and Prestwick (1280 compounds) chemical libraries, each of which contains multiple
azole antifungals, at ﬁnal concentrations of either 5 or 0.1 M. Wells with a total optical
density at 600 nm (OD600) of 0.1 were discarded from analysis as having populations
too small to allow reliable detection of population shifts. Rd scores were calculated for
each compound and converted to Z scores based on the mean and standard deviation
of the collection (Fig. 4). Hits were called based on Z scores of 3 or 3 in both
biological replicates. A complete list of hits with their associated Z scores from two
separate experiments is provided in Table 1. All nine of the azole antifungals present in
FIG 3 Legend (Continued)
(B) erg11/PTEF1-ERG11::CER (Erg11Hi), erg11/PYPT52-ERG11::dTOM (Erg11Med), and erg11/PACT1-ERG11::
GFP (Erg11Lo) promoter replacement strains were combined to create a second expression pool. (C) The
ERG11/ERG11/PTEF1-ERG11::CER (Erg11Hi) and ERG11/ERG11::dTOM (Erg11Med) strains from the ﬁrst pool
were combined with the erg11/PACT1-ERG11::GFP (Erg11Lo) strain from the second pool to create a
hybrid expression pool. (D) Three wild-type strains were tagged with CER, dTOM, and GFP to create a
control pool.
FIG 4 TAFiS can provide a reliable and sensitive HTP screening assay to detect target-speciﬁc chemical
interactions. An Erg11p expression pool consisting of ERG11/ERG11/PTEF1-ERG11::CER, ERG11/ERG11::
dTOM, and erg11/PACT1-ERG11::GFP cells was used to screen the NCC library in a 96-well format, at a
ﬁnal concentration of 0.1 M. Based on ﬂuorescence at 48 h, Rd values were calculated for each well and
then converted to Z scores relative to the collection as a whole, which are plotted above. Z scores for the
minus-drug control wells (DMSO solvent alone), negative, off-target control wells (0.1 M caspofungin
[CASPO]), and the positive, on-target control wells (0.1 M ﬂuconazole [FLU]) are also indicated.
TAFiS in C. albicans
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the NCC library were identiﬁed at one or both of the concentrations screened. Of the
16 azole antifungals found within the Prestwick collection, 14 (87.5%) yielded statisti-
cally signiﬁcant Z scores at one or both concentrations. Importantly, only two azole
antifungals, butoconazole and itraconazole, failed to yield Z scores of 3 at either
concentration, likely due to their very high potency. These experiments demonstrate
the reliability of TAFiS-based HTP screens to detect on-target chemical probes that are
active upon whole cells.
In addition to the azole antifungals, ﬁve other compounds induced a statistically
signiﬁcant population shift within the Erg11p expression pool. These were only de-
tected at the higher screening concentration (5 M) and with less signiﬁcant Z scores
than the azoles. Nonetheless, among these were amphotericin B, an antifungal that
directly binds ergosterol in the fungal plasma membrane (Table 1), and a second
antifungal, haloprogin, of unknown mechanism. Two closely related synthetic non-
steroidal estrogens, diethylstilbestrol and hexestrol, were also identiﬁed and selected
for follow-up analysis. Dose-response assays with the Erg11p expression pool con-
ﬁrmed that both compounds induced a spectral shift over an 8-fold concentration
range (Fig. 5A and B). In contrast, neither drug induced a shift in the tagged wild-type
control pool, conﬁrming that the observed shifts depend upon differential Erg11p
expression levels and are not an indirect consequence of spectral interference.
Dose-response experiments with individual strains revealed that both compounds
were growth inhibitory toward the low-expression strain, but neither was sufﬁcient to
inhibit the growth of wild-type C. albicans at concentrations up to 50 M (Fig. 5C and
D). To determine if either diethylstilbestrol or hexestrol is a bona ﬁde inhibitor of
ergosterol biosynthesis, sterol proﬁles of wild-type cells treated with either compound
TABLE 1 Erg11p expression pool hitsa
Library Concn Compound
Z score
Trial 1 Trial 2 Mean
NCC 5 M Fluconazole 23.8 12.8 18.30
Bifonazole 7.4 9.7 8.55
0.1 M Oxiconazole 12.1 11.9 12
Miconazole 11.1 11.5 11.30
Ketoconazole 10.9 11.4 11.15
Clotrimazole 10.8 11.2 11
Econazole 9.2 10.3 9.75
Voriconazole 10.1 7.5 8.80
Fluconazole 5.9 6.2 6.05
Itraconazole 5.5 4.7 5.10
Prestwick 5 M Fluconazole 18.7 18.1 18.40
Enilconazole 15.8 15.6 15.70
Terconazole 15.2 15.9 15.55
Bifonazole 11.6 11.6 11.60
Mupirocin 8.6 9.5 9.05
Diethylstilbestrol 6.6 7.8 7.20
Amphotericin B 6.2 6 6.10
Hexestrol 6.1 4.9 5.50
Haloprogin 5.2 4.1 4.65
0.1 M Tioconazole 12.3 12.7 12.50
Sertaconazole 12.4 12.6 12.50
Oxiconazole 12.4 12.4 12.40
Miconazole 12 11.9 11.95
Ketoconazole 11.2 11.7 11.45
Isoconazole 11.1 11.7 11.40
Clotrimazole 11.1 11.1 11.10
Sulconazole 10.9 10.3 10.60
Econazole 10.4 10.5 10.45
Fluconazole 7.2 7.8 7.50
Voriconazole 6.7 6.1 6.40
aShown are results from compounds identiﬁed from the NCC and Prestwick chemical libraries as causing
signiﬁcant population shifts in the Erg11p expression pool.
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FIG 5 Diethylstilbestrol and hexestrol induce population shifts within the FP-tagged Erg11p expression
pools over a broad concentration range. (A and B) ERG11/ERG11/PTEF1-ERG11::CER (Erg11Hi), ERG11/ERG11::
dTOM (Erg11Med), and erg11/PACT1-ERG11::GFP (Erg11Lo) cells were mixed in equal proportions, and
approximately 103 cells of this pool were inoculated into the wells of a 96-well plate in the presence of
a concentration range of (A) diethylstilbestrol or (B) hexestrol in YNB. After 48 h at 30°C, ﬂuorescence was
read at all three FPs’ wavelengths and expressed as a percentage of ﬂuorescence of the untreated wells.
The values presented are the averages and standard deviations of technical triplicates. (C and D)
Approximately 103 cells of ERG11/ERG11/PTEF1-ERG11::CER (Erg11Hi), ERG11/ERG11::dTOM (Erg11Med), or
erg11/PACT1-ERG11::GFP (Erg11Lo) were inoculated into the wells of a 96-well plate in the presence of
a concentration range of (C) diethylstilbestrol or (D) hexestrol in YNB. After 48 h at 30°C, growth was
measured as OD600 and is expressed as a percentage of that of the untreated control. The values
presented are the averages of technical duplicates and are representative of two independent
experiments.
TAFiS in C. albicans
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were analyzed. Treatment with either diethylstilbestrol or hexestrol resulted in a
decrease in ergosterol content and a substantial buildup of lanosterol (Table 2), a
proﬁle consistent with partial Erg11p inhibition, indicating they both engage the
intended target enzyme.
Validation of TAFiS with dihydrofolate reductase. To further validate TAFiS as a
viable chemical screening strategy, we applied it to dihydrofolate reductase (Dfr1p),
another historically important target for antimicrobial drug development (19–21). A
C. albicans Dfr1p expression pool was produced that included an overexpression strain
(Dfr1Hi [DFR1/DFR1/PENO1-DFR1]), a heterozygous strain (Dfr1Med [DFR1/dfr1]), and a
knockdown strain (Dfr1Lo [dfr1Δ/DFR1-DAmP]). The knockdown strain was produced
using a technique known as decreased abundance by mRNA perturbation (DAmP) (22),
to destabilize the mRNA transcript (Fig. 6A). Quantitative reverse transcription-PCR
(qRT-PCR) conﬁrmed a 30-fold differential in DFR1 mRNA abundance between Dfr1Hi
and Dfr1Lo strains (data not shown). Signiﬁcant population shifts within the Dfr1p
expression pool were detected over a 256-fold concentration range of the known
Dfr1p inhibitor methotrexate (MTX) (Fig. 6C). Treatment of the tagged Dfr1p pool with
5 M methotrexate yielded a Z= factor of 0.63  0.05 in 96-well plate-based assays,
again supporting the excellent quality of the assay. Finally, the tagged Dfr1p expression
pool was used to screen the same chemical libraries described above at a ﬁnal
concentration of 5 M. Only methotrexate produced a positive Z score of 3. (Note
that amethopterin, also identiﬁed as a hit, is the same chemical entity.) Unexpectedly,
21 compounds induced a statistically signiﬁcant inverse population shift (Z scores of
3), indicating that the Dfr1Hi strain was more sensitive than the Dfr1Lo strain
(Table 3).
Adapting TAFiS to a 384-well format. In order to increase throughput and
efﬁciency, we examined the performance of the TAFiS assay in 384-well plates using the
tagged Erg11p expression pool. Using volumes as low as 20 l, the tagged C. albicans
strains demonstrated excellent signal/background ratios versus the untagged controls
(data not shown). Furthermore, the Erg11p pool yielded Z= factors of 0.78  0.03 and
0.70  0.05 when treated with 5 and 0.1 M ﬂuconazole, respectively, indicating
excellent performance in this higher-density format. In conclusion, we have demon-
strated that TAFiS-based HTP assays can provide a reliable and highly sensitive ap-
proach to efﬁciently identify physiologically active and target-speciﬁc chemical probes.
DISCUSSION
The enormous costs and prolonged timelines associated with developing a new
pharmacotherapy underscore the desperate need to increase the efﬁciency of both
preclinical and clinical phases of drug discovery and development. Herein we describe
a new type of TB-WCS that can greatly expedite this process through the selection of
physiologically active and target-speciﬁc hits at the earliest possible stage, the primary
TABLE 2 Membrane sterol proﬁlesa
Sterol
% of total sterols in:
DMSO 5 M DSB 50 M DSB 5 M HEX 50 M HEX
Mean SD Mean SD Mean SD Mean SD Mean SD
Ergosta-5,8,22,24(28)-tetraenol 2.2 1.3 2.3 1.4
Zymosterol 8.2 0.1 4.4 0.1 2.9 0.2 6.6 0.9 4.4 0.8
Ergosterol 64.1 0.8 65.1 2.4 59.8 3.5 65.5 1.8 55.4 4.7
Ergosta-7,22-dienol 1.0 0.2 0.8 0.1
Ergosta-5,7,22,24(28)-tetraenol 1.0 0.2 1.1 0.3 1.1 0.3 1.2 0.4 1.7 1.3
Fecosterol 2.6 0.2 1.2 0.0 1.7 0.1
14-Methyl fecosterol 0.5 0.0 1.7 0.3 2.2 0.2
Ergosta-5,7-dienol 4.8 0.6 3.3 0.3 2.2 0.4 4.4 0.2 2.9 0.6
Episterol 4.6 0.5 2.5 0.1 1.6 0.1 3.2 0.7 2.1 0.2
Lanosterol 6.9 0.6 15.2 1.8 28.4 2.9 13.7 3.3 28.4 5.9
4,4-Dimethyl cholesta-8,24-dienol 4.7 0.4 3.8 0.6 2.3 0.4 3.7 1.7 3.0 0.7
aTreatment of wild-type C. albicans with either diethylstilbestrol (DSB) or hexestrol (HEX) results in altered sterol composition consistent with Erg11p inhibition.
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screen. TB-WCS assays have several major advantages over conventional target-based
and cell-based screening strategies and to a large extent combine the beneﬁts of both
into a single screening assay. First, chemical probes are selected that functionally
interact with a deﬁned molecular target, providing invaluable insight into each hit’s
MOA from the outset. Second, the selected target is presented within its native
environment, and thus only physiologically active small molecules that can access and
engage the target in its cellular context are recognized. Third, as the measured
outcome is comparative growth of strains expressing differing levels of target protein,
FIG 6 Modulation of Dfr1p expression affects C. albicans susceptibility to methotrexate. (A) Schematic
of strain construction. (B) C. albicans strains were grown in YNB at 30°C in the presence of various
concentrations of methotrexate. After 48 h, growth was measured via OD600 and expressed as a
percentage of that measured in the untreated control. The values presented are the averages of technical
triplicates. (C) C. albicans DFR1/DFR1/PENO1-DFR1::CER (Dfr1Hi), DFR1/DFR1::dTOM (Dfr1Med), and dfr1Δ/
DFR-DAmP::GFP (Dfr1Lo) strains were combined to create an expression pool. Approximately 1  103
cells of the pool were inoculated into the wells of a 96-well plate in the presence of a range of
methotrexate concentrations in YNB. After 48 h at 30°C, ﬂuorescence was read at all three FPs’
wavelengths and expressed as a percentage of ﬂuorescence of the untreated wells. The values presented
are the averages and standard deviations of technical triplicates.
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TB-WCS does not require puriﬁcation of the target protein itself or a speciﬁc and
HTP-compatible biochemical assay of its activity in order to identify relevant chemical-
target interactions. Indeed, this approach can readily be applied to targets that are not
amenable to biochemical analysis, such as noncatalytic proteins. Fourth, in addition to
identifying compounds that directly engage the selected target protein, TB-WCS assays
have the potential to identify compounds that indirectly interact with the selected
target protein. For instance, compounds that act upon compensatory or redundant
pathways that are required for survival when the primary target protein is limiting may
be expected to preferentially inhibit the growth of the knockdown strain. Compounds
that act by such indirect interactions are potentially of great value as they may uncover
new functional interactions between distinct cellular pathways or enhance the efﬁcacy
of on-target drugs and thus provide a basis for combination therapy. As such, TB-WCS
approaches have the potential to yield a diverse set of physiologically relevant chemical
probes that functionally interact with the selected target protein from a single primary
screen. Finally, compounds that lack speciﬁcity (e.g., that engage multiple targets) or
which are generally toxic to cells are unlikely to create the target-dependent ﬁtness
differential upon which these approaches depend and are thus eliminated at the
primary screening stage. Despite enormous potential advantages, TB-WCS approaches
are underutilized as a drug discovery strategy. While several important studies in the
pathogenic prokaryotes Staphylococcus aureus and Mycobacterium tuberculosis have
collectively established the validity of TB-WCS assays to discover on-target chemical
probes (6, 23, 24), each has been restricted by several technical issues that have limited
efﬁciency, sensitivity, and/or throughput of the screens. The approach described here
builds upon previous efforts but also incorporates several technological advances that
improve sensitivity and efﬁciency. First, nearly all TB-WCS assays that have been
described to date compared only the growth of a knockdown strain, with reduced
target expression, to a reference strain expressing normal levels of the target protein.
In our approach, the effects of each test compound on both target knockdown and
overexpression strains are simultaneously compared to a reference strain. This should
enhance both the dynamic range and sensitivity of the screening assay to detect
TABLE 3 Dfr1p expression pool hitsa
Library Concn Compound
Z score
Trial 1 Trial 2 Mean
NCC 5 M Methotrexate 4.0 4.4 4.2
Voriconazole 3.7 3.0 3.4
Miconazole 3.5 3.7 3.6
Triclabendazole 3.3 4.3 3.8
Disulﬁram 3.8 4.9 4.3
Mupirocin 4.2 5.2 4.7
Fluconazole 5.2 4.4 4.8
Oligomycin A 5.2 7.3 6.3
Fluvastatin 7.0 6.2 6.6
Cerivastatin 7.3 7.8 7.6
Hexachlorophene 11.0 5.0 8.0
Prestwick 5 M Amethopterin 5.9 6.8 6.3
Methotrexate 5.5 6.8 6.1
Pyrvinium 3.5 4.5 4.0
Atorvastatin 4.3 4.0 4.1
Pemetrexed 3.4 6.4 4.9
Benzethonium 3.2 8.0 5.6
Haloprogin 5.7 6.0 5.8
Disulﬁram 5.5 6.4 5.9
Chloroxine 4.7 7.3 6.0
Monensin 5.8 9.4 7.6
Merbromin 7.4 10.9 9.1
aShown are results from compounds from the NCC and Prestwick chemical libraries identiﬁed as causing
signiﬁcant population shifts in the Dfr1p expression pool.
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functionally interacting chemicals. Second, previous studies invariably used two-plate
assays that compare the growth of the reference and knockdown strains on separate
culture plates. With TAFiS, the overexpression, reference, and knockdown strains are
cocultured, and thus the relative growth of each strain is compared in a single well to
improve screening efﬁciency. Furthermore, the competitive ﬁtness basis of the TAFiS
assay enhances the sensitivity of this approach compared to previous two-plate assays,
as demonstrated by the identiﬁcation of two previously uncharacterized Erg11p inhib-
itors at sub-growth-inhibitory concentrations. Third, previous TB-WCS assays were based on
measurements such as colony size or zones of growth inhibition. These outcomes are
poorly suited to numerical measurement, automated data collection, and statistical analysis.
Through the incorporation of ﬂuorescent protein tags, TAFiS facilitates straightforward,
quantitative measurements of the relative growth of each strain, providing parameters that
are readily amenable to statistical analysis. This in turn simpliﬁes the selection, ranking, and
prioritization of hits according to the magnitude of the observed population shift and by
inference the strength of the compound-target interaction.
In selecting a well-characterized target protein (Erg11p) to validate the TAFiS
methodology, a large number of on-target inhibitors were present within the available
chemical libraries. However, due to their extreme potency, several of the highly
optimized azole antifungals apparently overwhelmed all strains within the Erg11p
expression pool, and thus no differential susceptibility/population shift was observed at
the standard screening concentration of 5 M. Accordingly, repeating the screen at a
lower concentration of 0.1 M actually identiﬁed more of the on-target azoles than at
the higher concentration. We anticipate that the occurrence of such extremely potent
on-target hits is unlikely when applying TAFiS to novel target proteins or when
screening unoptimized chemical libraries. Thus, we expect standard 5 to 10 M
compound concentrations to be appropriate for most TAFiS-based primary screens.
Additionally, these libraries both contain a number of highly growth-inhibitory com-
pounds of a variety of mechanisms, which is unlikely to pose signiﬁcant complications
when screening libraries that have not been enriched for bioactive compounds as these
collections have been. We also chose to screen two chemical libraries with signiﬁcant
overlap. Since hits were deﬁned relative to the collection, there were slightly different
thresholds of signiﬁcance for each library that probably account for the few discrep-
ancies between the hit lists for each.
As stated above, the potential exists for TAFiS to identify chemical probes that
directly engage the target protein as well as those that indirectly interact with the
target protein’s function: for example, by acting upon redundant or compensatory
pathways. However, our studies with Erg11p and Dfr1p indicate that TAFiS is excep-
tionally reliable at identifying on-target chemical probes, with few off-target hits
identiﬁed as causing positive population shifts (i.e., favoring the THi strain) in either
screen. This is particularly reassuring, given that suppression of Erg11p activity is
expected to alter membrane sterol composition and consequently plasma membrane
permeability (25). In such a situation, differential permeability of the strains within the
Erg11p expression pool might be expected to elevate the number of off-target com-
pounds identiﬁed. However, our results suggest this was a not major complication.
Intriguingly, several compounds were identiﬁed that resulted in negative Z scores with
the Dfr1p expression pool, indicating that the Dfr1Hi strain is more susceptible to these
agents than the Dfr1Lo strain. The exact meaning of these interactions is currently
unclear; however, it likely reﬂects the important role of folate in a myriad of metabolic
processes. Nonetheless, these preliminary studies collectively support that TAFiS can
provide an extremely reliable and efﬁcient means to identify physiologically active and
target-selective chemical probes.
One potential concern with TAFiS is that small molecules may interact with or
selectively quench the ﬂuorescent protein tags or that ﬂuorescence of a subset of
compounds may skew the FP signal intensity, resulting in false positives. However, this
was not a major problem in our chemical screens with Erg11p or Dfr1p, which used
cerulean, GFP, and dTomato to tag the individual strains. More recently, we have
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identiﬁed phi yellow ﬂuorescent protein (YFP) (13) as an exceptionally bright FP tag
under our standard TAFiS conditions. This will now enable the selection of closely
related ﬂuorescent proteins (e.g., CER, GFP, and YFP), which should ensure that
selective ﬂuorescent protein interactions are a rare occurrence. Nonetheless, such false
positives can be rapidly eliminated using a simple counterscreen—testing the effect of
each initial hit on an FP-tagged control pool of strains with no target protein expression
differential. Chemicals that induce spectral shifts in this control pool interfere with the
ﬂuorescent signal or detection and should be eliminated from further analysis. Finally,
the ﬁeld of ﬂuorescent protein engineering (26, 27), as well as the instruments used for
their detection, is rapidly evolving. We anticipate that as brighter FPs with more deﬁned
spectral proﬁles become available, the potential to multiplex TAFiS (i.e., to simultane-
ously screen multiple expression pools each representing a different target protein,
within a single well) will grow. Such multiplexing may for example facilitate the
simultaneous screening against all components of a pathway and will yield further cost
and time savings.
Moving forward, when applying TAFiS to additional systems, it is crucial to remem-
ber that there are a variety of both target- and compound-speciﬁc factors that may
inﬂuence both the magnitude and directionality of the observed population shifts.
Target-speciﬁc factors may include the magnitude of the target expression differential,
the consequences of hypo- and hyperactivity of the target protein under assay condi-
tions, and the subunit composition of the target. Maximizing the target protein
expression differential between the THi and TLo expression strains should theoretically
increase the range of concentrations over which an on-target probe differentially
impacts their ﬁtness and thus the dynamic range of the screen. In the case of an
essential gene, this is limited by the lower threshold of target protein activity that is
sufﬁcient to sustain cell viability. However, in the case of a nonessential protein, a target
gene deletion strain can be incorporated into the expression pool. Accordingly, the
population shifts expected to occur in response to a directly interacting chemical probe
would be different, in that a target deletion strain should be insensitive to on-target
modulators. Chemical-speciﬁc factors that may inﬂuence outcomes in the TAFiS assay
include the strength of the chemical-target interaction, the precise mode of action (e.g.,
inhibition versus activation), and the speciﬁcity of target engagement. Finally, TAFiS is
theoretically applicable to any microbial species that is culturable and genetically
tractable. We anticipate the development of closely related methodologies in a variety
of other microbes, including bacterial, protozoan, and fungal pathogens. Due to the
ease of recombinant protein expression in the yeast Saccharomyces cerevisiae, adapta-
tion of TAFiS to this system could facilitate chemical screens using targets derived from
nonculturable microbes, species not amenable to genetic manipulation, or even
disease-relevant human proteins.
MATERIALS AND METHODS.
Growth conditions. C. albicans was routinely grown on yeast extract-peptone-dextrose (YPD) agar
plates at 30°C, supplemented with 50 g/ml uridine for ura3 strains. Selection of C. albicans transfor-
mants was carried out on minimal YNB medium (6.75 g/liter yeast nitrogen base without amino acids, 2%
dextrose, 2% Bacto agar) supplemented with the appropriate auxotrophic requirements described for
S. cerevisiae (28) or with 50 g/ml uridine.
Plasmid construction. Plasmid pLUX (29) was kindly provided by William Fonzi (Georgetown
University), pMG2254 (8) and pMG1648 (30) were acquired from the Fungal Genetics Stock Center,
pENO1-dTom-NATr (9) was acquired from Addgene, pGateway-TagBFP (10) was acquired from Evrogen,
pFA-GFP (11) was kindly provided by James Konopka (Stony Brook University), and pGEMHIS1, pDDB57,
and pRSARG4ΔSpeI (31, 32), were kindly provided by Aaron Mitchell (Carnegie Mellon University). The
C. albicans expression vectors pKE1 (ACT1pr) (33) and pKE3 (ENO1pr) (34) have been previously described.
A detailed description of all other plasmid vectors constructed as part of these studies is provided in
Text S1 in the supplemental material. All oligonucleotides used in this study are listed in Table S1 in the
supplemental material.
C. albicans strain construction. BWP17 (32) and CAI4 (35), were kindly provided by Aaron Mitchell
(Carnegie Mellon University) and William Fonzi (Georgetown University), respectively. C. albicans was
transformed with DNA constructs using the lithium acetate procedure (36). Gene deletion strains were
constructed using the PCR-based approach described by Wilson et al. (32). All pKE3- and pKE4-based
vectors (URA3 selection marker), including pKE3-DFR1 and the pKE4-based FP expression constructs,
Butts et al.
September/October 2017 Volume 2 Issue 5 e00379-17 msphere.asm.org 14
 o
n
 D
ecem
ber 7, 2017 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
were cut with NheI prior to transformation of ura3 recipient C. albicans strains to target integration at
and fully restore the URA3-IRO1 locus. All pAR8-based vectors (ARG4 selection marker), including the
pAR8-ERG11 and the pAR8-based FP expression constructs, were cut with ClaI prior to transformation of
arg4 recipient C. albicans strains, to target integration at and restoration of the ARG4 locus. A detailed
description of how each gene deletion, target overexpression, promoter replacement, and FP-tagged
C. albicans strain was constructed is provided in Text S1.
Comparison of FP tag brightness. Several C. albicans transformants expressing each FP tag were
grown overnight in YPD at 30°C, diluted to approximately 5  103 cells/ml in YNB medium, and 200 l
of each cell suspension was transferred into the wells of a round-bottom 96-well plate. Following
incubation at 30°C for 48 h, ﬂuorescence intensity at the appropriate wavelengths and OD600 were
measured using a Cytation 5 plate reader (Bio-Tek Instruments, Inc.). The excitation/emission wave-
lengths used for tagBFP, CER, GFP, YFP, YFP, ZsYellow, dTOM, mCherry, and mPlum were 402/457,
433/475, 488/507, 510/531, 529/550, 533/558, 554/581, 587/612, and 590/649, respectively, using a 9-nm
bandwidth for both excitation and emission wavelengths. Fluorescence intensity was then normalized to
growth (OD600) and expressed relative to background ﬂuorescence, as measured in an isogenic, vector-
alone control strain. For the purpose of pooled experiments involving both YFP- and dTOM-tagged
strains, suboptimal wavelengths of 560/590 with 9-nm bandwidth were used for dTOM to minimize
spectral overlap.
Antifungal susceptibility testing. Stock solutions of ﬂuconazole, miconazole, voriconazole, terbin-
aﬁne, methotrexate, and caspofungin (Sigma-Aldrich) were prepared at 10 mg/ml in DMSO and diluted
as needed in the same solvent. Each C. albicans strain was grown overnight in YPD at 30°C and diluted
to 1  104 cells/ml in YNB medium, and 100 l of each cell suspension was transferred to the wells of
a round-bottom 96-well plate. An additional 100 l of YNB medium containing 2 the ﬁnal desired
concentration of each drug was then added to each well. The ﬁnal concentration of DMSO was 0.5% for
all treatments. Plates were then incubated at 30°C before growth was quantiﬁed after 24 and 48 h by
measuring OD600 using a Cytation 5 plate reader (Bio-Tek Instruments, Inc.). The growth of each strain at
each drug concentration was then expressed relative to the minus-drug (DMSO-alone) control.
The multistrain competition-based experiments were performed as described above, except the
individual FP-tagged strains were diluted to 1  104 cells/ml, mixed 1:1:1 to create the three-member
expression pools, before they were dispensed into the 96-well plates. Following incubation at 30°C for
48 h, OD600 and ﬂuorescence intensity were measured as described above. The relative growth of each
strain in the presence of drug was then expressed as a percentage of the same strain’s growth in the
minus-drug (DMSO-alone) control coculture, as measured by the ﬂuorescence intensity of the corre-
sponding FP tag.
Stress phenotypes. Each C. albicans strain was grown overnight in YPD at 30°C, the cell density was
adjusted to 108 cells/ml in sterile water, and serial 1:10 dilutions were performed in a 96-well plate. Cell
suspensions were then applied to agar plate surfaces using a sterile multipronged applicator. Resistance
to temperature stress was determined on YPD agar at 37 and 42°C, resistance to osmotic stress was
determined on YPD agar supplemented with 1 M sorbitol, and resistance to ionic stress was determined
on YPD agar plus 1 M NaCl. Sensitivity to metal ion stress was also tested on YPD agar supplemented with
either 50 M CuCl2, 50 M ZnCl2, or 10 mM MnCl2. Sensitivity to cell wall and membrane stress was
compared on YPD agar supplemented with either 5 mM caffeine, 100 g/ml Congo red, or 0.05% SDS.
The ability to utilize nonfermentable carbon sources was also compared on YPG agar (YPD agar with 3%
glycerol in place of dextrose).
Western immunoblot analysis. Each C. albicans strain was grown overnight in YPD at 30°C and then
subcultured to an OD600 of 0.2 in 10 ml of fresh YPD and grown for an additional 6 h at 30°C and collected
via centrifugation. Total protein extracts were prepared by resuspending cells in 200 l lysis buffer
(50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) with added protease inhibitor
cocktail (Roche) and 0.5-mm-diameter glass beads. Cells were lysed by 10 cycles of 20-s bursts with a
bead beater followed by 60 s on ice. The total protein concentration was determined using a Bradford
assay (Thermo Scientiﬁc) dye concentrate according to the manufacturer’s instructions. Fifty micrograms
of each protein lysate was fractionated on a 10% SDS-PAGE Mini-Protean TGX gel (Bio-Rad), transferred
to a nitrocellulose membrane, and blocked with 5% nonfat milk in 50 mM Tris (pH 7.5), 150 mM NaCl,
and 0.05% Tween 20 (TBST). The membranes were then probed with an anti-Erg11 antibody (generously
provided by Steve Kelly, Swansea University) (37) followed by anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (Bio-Rad) and with anti-PSTAIRE (Abcam, Inc.) antibody, which binds to
that consensus sequence, followed by anti-mouse HRP-conjugated secondary antibody (Bio-Rad) as an
internal loading control. HRP conjugates were detected with the Clarity ECL Western blotting detection
system (Bio-Rad). Blots were imaged using a G:Box Chemi XT-4 (Syngene) and analyzed using Image
Studio Lite (Li-Cor).
RNA isolation and qRT-PCR. Each C. albicans strain was grown overnight in YPD at 30°C and then
subcultured to an OD600 of 0.2 and incubated at 30°C with shaking for 6 h. Cells were pelleted by
centrifugation before total cellular RNA was extracted by the hot phenol method (38). cDNA was
synthesized from total RNA using the Verso cDNA synthesis kit (Thermo Scientiﬁc), in accordance with the
manufacturer’s instructions. Synthesized cDNA was used for the ampliﬁcation of ACT1 and the gene of
interest by PCR, using SYBR green PCR master mix, according to the manufacturer’s instructions.
Gene-speciﬁc primers were designed using the PrimerQuest Tool from IDT, synthesized by Integrated
DNA Technologies, Inc., and are listed in Table S1. The threshold cycle (2ΔΔCT) method was used to
calculate changes in gene expression among the strains (39). All experiments included both biological
and technical replicates in triplicate.
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Chemical libraries. The NIH Clinical Collection (NCC) library of 719 small molecules was provided by
the NIH Small Molecule Repository. The Prestwick library of 1,280 small molecules was purchased from
Prestwick Chemical. All library compounds were supplied at 10 mM in DMSO in a 96-well plate format.
These were diluted further in DMSO to ﬁnal concentrations of 1 or 0.02 mM, and 1-l volumes were
dispensed into round-bottom 96-well plates that were used for the chemical screens.
Chemical screening. The FP-tagged C. albicans strains expressing low, intermediate, and high levels
of target protein were grown overnight in YPD at 30°C, diluted to approximately 5  103 cells/ml in YNB
medium, and mixed 1:1:1 to create the three-member expression pools. One hundred ninety-nine
microliters of the mixed cell suspension (~103 cells) was then added to each well of each library plate,
resulting in ﬁnal compound concentrations of 5 or 0.1 M. After 24 and 48 h of incubation at 30°C, the
OD600 and ﬂuorescence at the appropriate wavelengths were measured at as described above. The
relative ﬁtness differential (Rd) was then calculated for each well as the log10 THi/TLo ﬂuorescence and
converted to Z scores using the average and standard deviation of the Rd score for the whole collection.
Hits were called based on a Z score of 3 or 3 in two independent replicates. Wells with little
detectable C. albicans growth (OD600 of 0.1) were discarded from analysis.
Sterol extraction and analysis. Twenty-ﬁve milliliters of YNB containing 1% DMSO and the
indicated concentration of diethylstilbestrol or hexestrol was inoculated with SC5314 at a concentration
of 1  103 cells/ml. Cultures were incubated at 37°C for 18 h. Nonsaponiﬁable lipids were extracted
using alcoholic KOH. Samples were dried in a vacuum centrifuge (Heto) and were derivatized by the
addition of 100 l 90% N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA)–10% trimethylsilyl (TMS
[Sigma]) with 200 l anhydrous pyridine (Sigma) and heating for 2 h at 80°C. TMS-derivatized sterols
were analyzed and identiﬁed by gas chromatography-mass spectrometry (GC-MS) (Thermo 1300 gas
chromatograph coupled to a Thermo ISQ mass spectrometer; Thermo Scientiﬁc) with reference to
retention times and fragmentation spectra for known standards. GC-MS data ﬁles were analyzed
using Xcalibur software (Thermo Scientiﬁc) to determine sterol proﬁles for all isolates and for
integrated peak areas (40).
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